Alivus Life Sciences Receives ₹2.6 Crore Tax Demand Order from Income Tax Dept.
Alivus Life Sciences received a ₹2.6 crore tax demand order from the Income Tax Department for AY 2023-24. The demand is due to disallowances of expenditure. The company believes there is no material financial or operational impact and plans to appeal the order.
The company has explicitly stated that there is no material impact on its financial, operational, or other activities due to this tax demand order. The amount of the demand, while significant, is not considered material in the context of the company's overall financials.
The company has received a tax demand, which is a negative event. However, the company explicitly states that there is no material impact and that they intend to appeal the order. This mitigates the immediate negative impact, leading to a neutral sentiment.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has received an order from the Income Tax Department, Faceless Assessment Unit, concerning the assessment year 2023-24 (Financial Year 2022-23).
The order, passed under Section 143(1) read with Section 144B of the Income Tax Act, 1961, and dated March 20, 2026, was received by the company around 7:30 pm on March 20, 2026. The Income Tax Department has completed the regular assessment and issued a tax demand, including applicable interest, amounting to ₹2,60,67,810. This demand arises from disallowances of expenditure under Section 37(1).
The company has stated that this order has no material impact on its financial, operational, or other activities. Alivus Life Sciences Limited intends to assess its options and exercise its right to appeal before the appellate authority, as the order is currently appealable.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.